Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist

1. A composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof, and (b) a muscarinic receptor antagonist, wherein the muscarinic receptor antagonist is atropine or glycopyrrolate.

2. A composition according to claim 1 , in which the PDE3/PDE4 inhibitor (a) is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3 -(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a ]soquinolin-4-one.

3. A composition according to claim 1 , in which the muscarinic receptor antagonist (b) is atropine.

4. A composition according to claim 1 , in which the muscarinic receptor antagonist (b) is glycopyrrolate.

5. A composition according to claim 1 , wherein the composition is a fixed combination.

6. A pharmaceutical composition comprising a composition as defined in claim 1 and one or more pharmaceutically acceptable carriers, diluents, or excipients.

7. A pharmaceutical composition according to claim 6 which is for administration by dry powder inhaler (DPI) or metered-dose inhaler (MDI).

8. A method of treating a disease or condition which is based on acute or chronic obstruction of bronchi or vessels in the respiratory tract, in a subject in need thereof, which method comprises administering to said subject a therapeutically effective, non-toxic amount of a composition comprising (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist, wherein the muscarinic receptor antagonist is atropine or glycopyrrolate.

9. A method according to claim 8 , wherein the disease or condition is asthma.

10. A method according to claim 8 , wherein the disease or condition is chronic obstructive pulmonary disease (COPD).

11. A method according to claim 8 , wherin said subject is a human.

12. A method of treating a disease or condition which is based on acute or chronic obstruction of bronchi or vessels in the respiratory tract in a subject in need thereof, which method comprises administering to said subject (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof simultaneously, separately or sequentially in combination with (b) a muscarinic receptor antagonist, wherein the muscarinic receptor antagonist is atropine or glycopyrrolate.

13. A method of treating a disease or condition which is based on acute or chronic obstruction of bronchi or vessels in the respiratory tract, which method comprises administering to said subject (b) a muscarinic receptor antagonist simultaneously in combination with (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof, wherein the muscarinic receptor antagonist is atropine or glycopyrrolate.